Effects of montelukast on burn wound healing in a rat model

Turtay, Muhammet G.; Firat, Cemal; Samdanci, Emine; Oguzturk, Hakan; Erbatur, Serkan; Colak, Cemil
December 2010
Clinical & Investigative Medicine;Dec2010, Vol. 33 Issue 6, pE413
Academic Journal
Purpose: Montelukast, a selective cysteinyl leukotriene D4-receptor antagonist, is used in the treatment of asthma. In a rat model, our aim was to investigate the e!ects of montelukast, alone or in combination with topical antibiotics, on local burn wound healing. Methods: Rats were randomly allocated to four groups a"er local burn development: Group 1; rats were le" to secondary healing without treatment, Group 2; a dose of 10#mg/ kg montelukast was given by gastric gavage once a day for 10 days, Group 3; rats were treated with topical pomade (bacitracin neomycin sulphate), and Group 4; rats were treat with a combination of topical antibiotic and montelukast (10 mg/kg were given by gastric gavage once a day for 10 days). Skin biopsies were taken on days 3, 10, 14, and 20 relative to burn induction. Results: Reepithelialization in the pomade and montelukast+pomade groups on the 10th day was significantly greater, in comparison with control and montelukast groups (p<0.05). For the montelukast group, edema (on the 14th day) and angiogenesis, fibroblast proliferation, edema and macrophage infiltration (on the 20th day) were statistically improved in comparison with the control group (p<0.05). For the montelukast+pomade group, angiogenesis, fibroblast proliferation and macrophage infiltration (on the 10th day), and angiogenesis, fibroblast proliferation, edema and macrophage infiltration (on the 14th and 20th days) were statistically improved in comparison with the control group (p<0.05). Conclusion: In conclusion, montelukast was e!ective on burn wound healing. Moreover, the e!ect was amplified when combined with topical antibiotics applied in the early stage of burn wound healing.


Related Articles

  • The Use of Leukotriene Modifying Drugs in Asthma and Other Respiratory Diseases. J.A. Corless; M. Paracha // Current Drug Targets - Inflammation & Allergy;Sep2002, Vol. 1 Issue 3, p271 

    Only rarely in modern medicine is an entirely new class of drug developed. Recently, a number of drugs that act as leukotriene modifiers (LTM's) have been licensed for use in the treatment of asthma. Airway obstruction in asthma has two key components-bronchoconstriction of airway smooth muscle...

  • Leukotriene modifiers in the treatment of asthma. Sampson, Anthony; Holgate, Stephen // BMJ: British Medical Journal (International Edition);04/25/98, Vol. 316 Issue 7140, p1257 

    Editorial. Looks at the treatment of asthma with the use of leukotriene modifiers. Reference to leukotriene synthesis inhibitors and cysteinyl leukotriene receptor antagonists, which are the two types of leukotriene modifiers; Detailed information on the two leukotriene modifiers; Relation to...

  • Montelukast beneficial in asthma exacerbations.  // Pulse;10/27/2010, Vol. 70 Issue 32, p9 

    The article discusses a study conducted in Great Britain which suggests the use of leukotriene receptor antagonists during acute asthma exacerbations.

  • montelukast.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1490 

    A definition of the medical term "montelukast," which refers to an oral leukotriene inhibitor for asthma treatment, is presented.

  • Should Leukotriene Antagonists Have Higher Priority for Asthma Control? Kuritzky, Louis // Neurology Alert;Jul2011, Vol. 29 Issue 11, p14 

    The article focuses on research on the efficacy of leukotriene inhibitors (LKT) in asthma control conducted by D. Price and colleagues and published in a 2011 issue of the "New England Journal of Medicine."

  • Breathe easier. Gordon, Mary Ebitt // Self;Apr97, Vol. 19 Issue 4, p95 

    Reports on the availability of leukotriene receptor antagonists or inhibitors, oral medications for asthma sufferers. Drugs in the category introduced in the market; Need for doctor's prescription on the kind of drug suited for severity of asthma.

  • Challenges in the Management of Severe Asthma: Role of Current and Future Therapies. Oliveinstein, Ron; Al Jahdali, Hamdan; Alkhamis, Nouf; Halwani, Rabih; Al-Muhsen, Saleh; Hamid, Qutayba // Current Pharmaceutical Design;3/1/2011, Vol. 17 Issue 7, p703 

    No abstract available.

  • Staple drugs, new treatments and roles hope to solve Asthma's... Southwick, Karen // Managed Healthcare;Jun98, Vol. 8 Issue 6, p44 

    Discusses the effectiveness of the drugs for the treatment of asthma. Number of people in the United States died from asthma annually; Effectiveness of the anti-leukotrienes; Price of the drug.

  • Should Leukotriene Antagonists Have Higher Priority for Asthma Control?  // OB/GYN Clinical Alert;Jul2011 Clinical Briefs in Primary, Vol. 16 Issue 7, p14 

    The article presents a research on the role of leukotriene inhibitors (LKT) in inhaled corticosteroids (ICS) for "controller" maintenance medication for persistent asthma.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics